p53 Activation: A Case against Sir
- 1 May 2008
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 13 (5), 377-378
- https://doi.org/10.1016/j.ccr.2008.04.009
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's DiseaseScience, 2007
- Sirtuins in mammals: insights into their biological functionBiochemical Journal, 2007
- Mammalian sirtuins—emerging roles in physiology, aging, and calorie restrictionGenes & Development, 2006
- A practical view of ‘druggability’Current Opinion in Chemical Biology, 2006
- Improving cancer therapy by non-genotoxic activation of p53European Journal Of Cancer, 2003
- Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeiaCurrent Opinion in Chemical Biology, 2003
- Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulationCurrent Opinion in Cell Biology, 2003
- hSIR2SIRT1 Functions as an NAD-Dependent p53 DeacetylaseCell, 2001
- Negative Control of p53 by Sir2α Promotes Cell Survival under StressCell, 2001